<DOC>
	<DOCNO>NCT01995500</DOCNO>
	<brief_summary>The NIREUS study aim demonstrate angiographic non-inferiority BioNIR Ridaforolimus Eluting Coronary Stent System ( hereafter refer BioNIR ) comparison Resolute zotarolimus-eluting stent ( hereafter refer Resolute ) . The trial hypothesis BioNIR non-inferior Resolute primary endpoint angiographic in-stent late loss 6 month .</brief_summary>
	<brief_title>Angiography Study BioNIR Drug Eluting Stent System ( NIREUS )</brief_title>
	<detailed_description>This prospective , multi-center , single-blind , two-arm , 2:1 randomize clinical trial . Randomization stratify presence medically treat diabetes vs. medically treat diabetes site . Lesions plan treat must declare recorded time randomization . Angiographic follow-up perform 6 month . Clinical follow-up perform 30 day , 6 month , 1 , 2 , 3 , 4 , 5 year post randomization . The Primary Endpoint in-stent late loss 6 month measure angiographic core laboratory . Angiographic Secondary Endpoints evaluate 6 month : - In-segment late loss - Follow-up percent diameter stenosis ( in-stent in-segment ) - Binary restenosis ( in-stent in-segment ) - Length pattern angiographic restenosis ( Mehran classification ) Clinical Secondary Endpoints evaluate 30 day , 6 month , 1 , 2 , 3 , 4 5 year , except note , : - Device , Lesion , Procedure Success time baseline procedure - Target lesion failure ( TLF ; composite cardiac death , target vessel-related MI , ischemia-driven TLR ) - Major adverse cardiac event ( MACE ; composite rate cardiac death , MI ischemia-driven TLR ) - Target vessel failure ( TVF ; composite rate death , target vessel-related MI , ischemia-driven TVR ) - Overall Mortality - Cardiac Death - Myocardial Infarction - Target Vessel Related MI - Ischemia-driven TLR - Ischemia-driven TVR - Stent Thrombosis ( ARC definite probable )</detailed_description>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>Age ≥ 18 year Patient indication PCI include angina ( stable unstable ) , silent ischemia ( absence symptom visually estimate target lesion diameter stenosis ≥70 % , positive noninvasive stress test , FFR ≤0.80 must present ) , NSTEMI , recent STEMI . For STEMI time presentation first treat hospital , whether transfer facility study hospital , must &gt; 24 hour prior randomization enzyme level ( CKMB Troponin ) demonstrate either enzyme level peak . Nontarget vessel PCI allow prior randomization depend time interval condition follow : . During Baseline Procedure : i. PCI nontarget vessel perform baseline procedure immediately prior randomization successful uncomplicated define : &lt; 50 % visually estimate residual diameter stenosis , TIMI Grade 3 flow , dissection ≥ NHLBI type C , perforation , persistent ST segment change , prolong chest pain , TIMI major BARC type 3 bleeding . b . Less 24 hour prior Baseline Procedure : . Not allow ( see exclusion criterion # 3 ) . c. 24 hours30 day prior Baseline Procedure : i. PCI nontarget vessel 24 hour 30 day prior randomization successful uncomplicated define . ii . In addition , case nontarget lesion PCI occur 2472 hour prior baseline procedure , least 2 set cardiac biomarkers must draw least 6 12 hour nontarget vessel PCI . If cardiac biomarkers initially elevate local laboratory upper limit normal , serial measurement must demonstrate biomarkers fall . d. Over 30 day prior Baseline Procedure : iii . PCI nontarget vessel perform great 30 day prior procedure whether successful uncomplicated . Patient legal guardian willing able provide inform write consent comply followup visit test schedule . Angiographic inclusion criterion ( visual estimate ) : Treatment three de novo target lesion , maximum one de novo target lesion per vessel Target lesion ( ) must locate native coronary artery visually estimate diameter ≥2.5 mm ≤4.25 mm diameter stenosis ≥50 % &lt; 100 % . Lesion must ≤28 mm long cover single study stent maximum length 33 mm ( note : multiple focal stenosis may consider single lesion enrol completely cover one stent ) . TIMI flow 2 3 If one target lesion treat , RVD lesion length must meet criterion . Planned procedure baseline procedure either target nontarget vessel . STEMI within 24 hour initial time presentation first treat hospital , whether transfer facility study hospital enzyme level ( either CKMB Troponin ) peak . PCI within 24 hour precede baseline procedure randomization . Nontarget lesion PCI target vessel within 12 month baseline procedure . History stent thrombosis . Cardiogenic shock ( defined persistent hypotension ( systolic blood pressure &lt; 90 mm/Hg 30 minute ) require pressor hemodynamic support , include IABP . Known LVEF &lt; 30 % . Subject intubate . Relative absolute contraindication DAPT 12 month ( include plan surgery delay , subject indicate chronic oral anticoagulant treatment ) . Hemoglobin &lt; 10 g/dL . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 . White blood cell ( WBC ) count &lt; 3,000 cells/mm3 . Clinically significant liver disease . Renal disease define estimate creatinine clearance &lt; 40 mL/min use CockcroftGault equation . Active peptic ulcer active bleeding site . Bleeding site within prior 8 week require active medical surgical attention . History bleed diathesis coagulopathy likely refuse blood transfusion . If femoral access plan , significant peripheral arterial disease precludes safe insertion 6F sheath . Cerebrovascular accident transient ischemic attack within past 6 month , permanent neurologic defect attribute CVA . Known allergy study stent component , whether BioNIR Resolute , e.g . cobalt , nickel , chromium , molybdenum , Carbosil® , PBMA , Biolinx polymer , limus drug ( ridaforolimus , zotarolimus , tacrolimus , sirolimus , everolimus , similar drug analogue derivative similar compound ) . Known allergy protocolrequired concomitant medication aspirin , DAPT ( clopidogrel , prasugrel , ticagrelor ) , heparin bivalirudin , iodinate contrast adequately premedicated . Any comorbid condition may cause noncompliance protocol ( e.g . dementia , substance abuse , etc . ) reduce life expectancy &lt; 24 month ( e.g . cancer , severe heart failure , severe lung disease ) . Patient participate plan participate investigational drug device clinical trial reach primary endpoint . Women pregnant breastfeeding ( woman childbearing potential must negative pregnancy test within one week treatment ) . Women intend become pregnant within 12 month baseline procedure ( woman childbearing potential sexually active must agree use reliable method contraception time screen 12 month baseline procedure ) . Patient receive organ transplant wait list organ transplant . Patient receive schedule receive chemotherapy within 30 day time baseline procedure . Patient receive oral intravenous immunosuppressive therapy know lifelimiting immunosuppressive autoimmune disease ( e.g. , HIV ) . Corticosteroids allow . Angiographic Exclusion Criteria ( visual estimate ) : Unprotected leave main lesion ≥30 % , plan leave main intervention . Stenting ostial LAD LCX lesion ( stenting diseased segment within 5 mm unprotected leave main coronary artery ) . Lesions locate within arterial saphenous vein graft distal diseased arterial saphenous vein graft . Moderately heavily calcified lesion . Moderately heavily tortuous angulated lesion vessel . Bifurcation lesion presence side branch ≥2.0 mm diameter . Lesions contain thrombus . Total occlusion . Instent restenotic lesion lesion present within 10 mm previously implant stent . Lesions require predilatation device simple balloon angioplasty ( e.g . atherectomy cutting/scoring balloon ) . Another lesion target vessel present require high probability require PCI baseline procedure within 6 month baseline procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>CAD</keyword>
	<keyword>PCI</keyword>
	<keyword>ACS</keyword>
	<keyword>non ACS</keyword>
	<keyword>BioNIR</keyword>
	<keyword>DES</keyword>
</DOC>